Clinical trials: Overweight and Obesity
Obesity
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 35 kg/m² or more and at least one health problem related to their weight, or a BMI of 27 kg/m² or more and at least two health…
- Trial name
- SYNCHRONIZE™JP (NCT06176365)
- Testing
- Survodutide
- Where
- 28 sites in Japan
- Volunteers
- 274 people
- Sponsor
- Boehringer Ingelheim
Obesity
One-Year Study of S1B-509 vs Placebo for Weight Loss
This is a study to test whether S1B-509 given orally daily helps people with overweight or obesity to lose more weight than with placebo over a year.
- Trial name
- NCT06517797
- Testing
- S1B-509 low dose, S1B-509 High Dose
- Volunteers
- 210 people
- Sponsor
- S1 Biopharma, Inc.
Obesity, Obesity-related Complications
Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam
This study is investigating how common weight related health problems are in people of different weight categories in India, Pakistan, Philippines, and Vietnam.
- Trial name
- WEIGHT DIVERSE (NCT06843473)
- Testing
- No treatment given
- Where
- 4 sites in India, Pakistan and 2 more
- Volunteers
- 1,170 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects.
- Trial name
- NCT02475317
- Testing
- Maralixibat, Volixibat
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Obesity, Weight Loss
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
The primary objective of this study is to assess, over a period of 12 months, the effect on weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in overweight/obese patients after an initial…
- Trial name
- MODERATO (NCT00678483)
- Testing
- rimonabant (SR141716)
- Where
- 5 sites in Croatia, Finland and 3 more
- Volunteers
- 331 people
- Sponsor
- Sanofi
Obesity
ULTIMATE Study for Weight Loss
The purpose of this study is to help find out more about how the Primary Obesity Surgery Endoluminal (POSE) procedure makes patients feel less hungry and fuller faster, leading to weight loss.
- Trial name
- ULTIMATE (NCT01771276)
- Testing
- g-Cath Suture Anchor Delivery Catheter
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- USGI Medical
Obesity
A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.
The purpose of this study is to determine the effects of TM30339 on weight loss in obese individuals after 28 days dosing.
- Trial name
- NCT00746824
- Volunteers
- 192 people
- Sponsor
- 7TM Pharma A/S
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Substance Dependence
Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement
This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese.
- Trial name
- NCT01039454
- Testing
- GSK598809 Capsules
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Efficacy of Polyglucosamine Long Term Treatment
The polyglucosamine, specification L112, is a medical device and in this clinical trial used for weight reduction in moderately obese participants following a long term treatment lasting 12 months.
- Trial name
- NCT02682277
- Testing
- polygucosamine
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Overweight, Obesity
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks.
- Conditions
- Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression
- Trial name
- NCT07889570
- Testing
- Evolv GLP-1 Group, Control Group
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Evolv
Obesity and Cardiovascular Risk
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation.
- Trial name
- QUELL-CV (NCT07656727)
- Testing
- Oral BGE-102
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- BioAge Labs, Inc.
Obesity, Overweight
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
- Trial name
- NCT03479762
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia, Cardiovascular Risk Factor
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects
This clinical study aims to assess the efficacy of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism in moderate hypercholesterolemic subjects.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Overweight and Obesity
- Trial name
- HEART (NCT04760951)
- Testing
- TOTUM-070
- Where
- 4 sites in France, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Obesity, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
- Trial name
- NCT06305351
- Testing
- K-757 and K-833 QD, K-757 and K-833 BID
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TriGemX Bio, Inc.
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than…
- Trial name
- RASMUS (NCT07527195)
- Testing
- Cagrilintide, Semaglutide
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.